{
    "info": {
        "nct_id": "NCT05269381",
        "official_title": "A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)",
        "inclusion_criteria": "* PRE-REGISTRATION COHORT 1 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies\n* PRE-REGISTRATION COHORT 1 ONLY: Has cancer progression after at least one line of standard of care systemic treatment\n* PRE-REGISTRATION COHORT 2 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies that pembrolizumab is Food and Drug Administration (FDA) approved indication including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC) or other solid tumors that will benefit from pembrolizumab per the treating physician's judgment.\n* PRE-REGISTRATION COHORT 2 ONLY: Patient is eligible to receive pembrolizumab with or without chemotherapy per the treating physician's judgement or has been on pembrolizumab through compassionate use\n* PRE-REGISTRATION: Age >= 18 years\n* PRE-REGISTRATION: Willing to provide mandatory tissue specimens per protocol\n\n  * NOTE: This includes mandatory fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing unless patient had sequencing under Mayo Institutional Review Board (IRB) protocol #13-000942, #14-004094, or #21-007742 and has been identified for potential production of REAL Neo vaccine. Patients who had sequencing under Mayo IRB protocol #13-000942, #14-004094, or #21-007742 and have been identified for potential production of REAL Neo vaccine are allowed to proceed with neoantigen production.\n* PRE-REGISTRATION: Measurable disease as defined by RECIST (version 1.1) criteria\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease or non-measurable disease\n* PRE-REGISTRATION: Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy\n* PRE-REGISTRATION: Provide written informed consent\n* PRE-REGISTRATION: Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n* PRE-REGISTRATION: Willing to provide mandatory blood specimens for correlative research\n* PRE-REGISTRATION: Negative pregnancy test done =< 7 days prior to pre-registration for persons of childbearing potential only\n\n  * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* PRE-REGISTRATION: Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle\n* PRE-REGISTRATION: Willing to receive a tetanus vaccination if subject has not had one =< 1 year prior to pre-registration\n* PRE-REGISTRATION: Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n* PRE-REGISTRATION: Anticipated life expectancy of > 6 months\n* PRE-REGISTRATION: Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see below limits for inclusion) or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1, except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo).\n* PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent transfusion)\n* PRE-REGISTRATION: Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 X 10^9/L (obtained =< 28 days prior to pre-registration)\n* PRE-REGISTRATION: Platelet count >= 100,000/mm^3 or >= 100 X 10^9/L (obtained =< 28 days prior to pre-registration) (Must be >=7 days after most recent transfusion)\n* PRE-REGISTRATION: Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to pre-registration)\n* PRE-REGISTRATION: Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases (obtained =< 28 days prior to pre-registration)\n* PRE-REGISTRATION: Creatinine =< 1.5 x ULN OR calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to pre-registration)\n* PRE-REGISTRATION: International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy (obtained =< 28 days prior to pre-registration)\n* REGISTRATION COHORT 1 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies\n* REGISTRATION COHORT 1 ONLY: Has cancer progression after at least one line of standard of care systemic treatment\n* REGISTRATION COHORT 2 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies that pembrolizumab is FDA approved indication (including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC) or other solid tumors that will benefit from pembrolizumab per the treating physician's judgement.\n* REGISTRATION COHORT 2 ONLY: Pembrolizumab without chemotherapy remains as a reasonable treatment option at the treating physician's decision\n* REGISTRATION: Age >= 18 years\n* REGISTRATION: Soft tissue lesion amenable for adequate tissue sampling\n\n  * NOTE: It should not be tumor which was radiated in the past.\n* REGISTRATION: Successful sequencing and production of REAL-Neo vaccine\n* REGISTRATION: Measurable disease as defined by RECIST (version 1.1) criteria\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease or non-measurable disease\n* REGISTRATION: ECOG Performance Status (PS) 0 or 1\n* REGISTRATION: Anticipated life expectancy of > 6 months\n* REGISTRATION: Hemoglobin >= 9.0 g/dl (obtained =< 14 days prior to registration)\n* REGISTRATION: Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)\n* REGISTRATION: Platelet count >= 100,000/mm^3 (obtained =< 14 days prior to registration)\n* REGISTRATION: Total bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)\n* REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 14 days prior to registration)\n* REGISTRATION: PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy (obtained =< 14 days prior to registration)\n* REGISTRATION: Calculated creatinine clearance >= 50 ml/min using the Cockcroft-Gault formula (obtained =< 14 days prior to registration)\n* REGISTRATION: Provide written informed consent\n* REGISTRATION: Willing to provide mandatory blood specimens for correlative research\n* REGISTRATION: Willing to provide mandatory tissue specimens for correlative research\n* REGISTRATION: Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n* REGISTRATION: Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy\n* REGISTRATION: Negative pregnancy test done =< 14 days prior to registration for persons of childbearing potential only\n\n  * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* REGISTRATION: Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle\n* REGISTRATION: Willing to receive a tetanus vaccination if subject has not had one =< 1 year prior to pre-registration\n* REGISTRATION: Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see below limits for inclusion) or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1, except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* PRE-REGISTRATION: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant person\n  * Nursing person unwilling to stop breast feeding\n  * Person of childbearing potential who are unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle\n* PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* PRE-REGISTRATION: History of myocardial infarction =< 6 months prior to pre-registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.\n* PRE-REGISTRATION: Acute, reversible effect(s) of prior therapy not recovered to baseline regardless of interval since last treatment\n* PRE-REGISTRATION: Uncontrolled illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Psychiatric illness/social situations\n  * Congestive heart failure with New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease\n  * Stroke =< 3 months prior to pre-registration\n  * Significant cardiac arrhythmia or unstable angina\n  * Any other conditions that would limit compliance with study requirements\n* PRE-REGISTRATION: Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n* PRE-REGISTRATION: Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm, except for pembrolizumab\n* PRE-REGISTRATION: Any prior hypersensitivity or adverse reaction to GM-CSF\n* PRE-REGISTRATION: Other active malignancy =< 3 years prior to pre-registration\n\n  * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix\n  * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer\n* PRE-REGISTRATION: Known history of active autoimmune disease that has required systemic treatment in the =<30 days (i.e., with use of disease modifying agents, corticosteroids >10 mg daily prednisone equivalent, or other immunosuppressive drugs) prior to pre-registration.\n\n  * NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with celiac disease controlled with diet modification are not excluded\n* REGISTRATION: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception\n* REGISTRATION: Any of the following prior therapies:\n\n  * Chemotherapy, experimental drugs (except for pembrolizumab), or small molecules inhibitors (except for endocrine therapies) =< 3 weeks prior to registration\n  * Radiation =< 2 weeks prior to registration\n  * Major Surgery =< 4 weeks prior to registration\n  * Received a live vaccine =< 30 days prior to registration\n  * NOTE: Recent anti-PD1 or anti-PD-L1, such as pembrolizumab, nivolumab, atezolizumab, and durvalumab, is allowed, but the last dose of anti-PD-1 or anti-PD-L1 treatment should be more than 21 days from first dose of vaccination on the study (for Cohort 2 only)\n  * Palliative radiation therapy for symptoms control including, but not limited to, bone metastatic lesion radiation therapy is allowed, but the last dose of radiation therapy should be more than 14 days from the first dose of vaccination on the study\n* REGISTRATION: CTCAE >= Grade 3 treatment-emergent adverse event (TEAE) to prior checkpoint inhibitor, TEAE requiring systemic corticosteroids (> 10 mg daily prednisone equivalent), or permanent treatment discontinuation due to toxicity\n* REGISTRATION: Neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy), or a history of rhabdomyolysis\n* REGISTRATION: Active autoimmune diseases that require chronic systemic steroids (> 10 mg daily prednisone equivalent) or immunosuppressive agents\n* REGISTRATION: Requirement for systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications =< 14 days prior to registration\n\n  * NOTE: Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease\n* REGISTRATION: Evidence of leptomeningeal disease\n* REGISTRATION: Central nervous system metastases that are untreated, symptomatic, or require steroids > 10 mg daily prednisone equivalent\n\n  * NOTE: Patients with history of stable treated brain metastases are eligible. Stable treated metastases are defined as follows: No evidence of progression for >= 4 weeks on brain imaging (either magnetic resonance imaging [MRI] or computed tomography [CT] scan)\n* REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* REGISTRATION: Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
            "criterions": [
                {
                    "exact_snippets": "Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
                    "criterion": "willingness to return for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "Active Monitoring Phase of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",
            "criterions": [
                {
                    "exact_snippets": "urine test is positive or cannot be confirmed as negative",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "positive",
                                "cannot be confirmed as negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "a serum pregnancy test will be required",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Platelet count >= 100,000/mm^3 (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to pre-registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to pre-registration)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained =< 28 days prior to pre-registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Successful sequencing and production of REAL-Neo vaccine",
            "criterions": [
                {
                    "exact_snippets": "Successful sequencing",
                    "criterion": "sequencing",
                    "requirements": [
                        {
                            "requirement_type": "success",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "production of REAL-Neo vaccine",
                    "criterion": "REAL-Neo vaccine production",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Willing to provide mandatory blood specimens for correlative research",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide mandatory blood specimens for correlative research",
                    "criterion": "blood specimen provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "specimen type",
                            "expected_value": "blood"
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "correlative research"
                        },
                        {
                            "requirement_type": "mandatory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle",
            "criterions": [
                {
                    "exact_snippets": "Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of pre-registration through 6 months after the final vaccine cycle"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Hemoglobin >= 9.0 g/dl (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dl",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "hemoglobin measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see below limits for inclusion) or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1, except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo).",
            "criterions": [
                {
                    "exact_snippets": "Recovered from all toxicities associated with prior treatment to acceptable baseline status",
                    "criterion": "toxicities associated with prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": "acceptable baseline status"
                        }
                    ]
                },
                {
                    "exact_snippets": "for laboratory toxicity see below limits for inclusion",
                    "criterion": "laboratory toxicity",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "see below limits for inclusion"
                        }
                    ]
                },
                {
                    "exact_snippets": "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1",
                    "criterion": "NCI CTCAE toxicity grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo)",
                    "criterion": "toxicities not considered a safety risk per treating investigator",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent transfusion)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to pre-registration",
                    "criterion": "hemoglobin measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be >= 7 days after most recent transfusion",
                    "criterion": "time since most recent transfusion",
                    "requirements": [
                        {
                            "requirement_type": "time since transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Platelet count >= 100,000/mm^3 or >= 100 X 10^9/L (obtained =< 28 days prior to pre-registration) (Must be >=7 days after most recent transfusion)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3 or >= 100 X 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 100000,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "10^9/L"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to pre-registration",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be >=7 days after most recent transfusion",
                    "criterion": "time since most recent transfusion",
                    "requirements": [
                        {
                            "requirement_type": "interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Total bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
            "criterions": [
                {
                    "exact_snippets": "Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
                    "criterion": "willingness to return for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "Active Monitoring Phase"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Negative pregnancy test done =< 14 days prior to registration for persons of childbearing potential only",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test done =< 14 days prior to registration",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for persons of childbearing potential only",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Eastern Cooperative Oncology Group (ECOG) of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Measurable disease as defined by RECIST (version 1.1) criteria",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by RECIST (version 1.1) criteria",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST (version 1.1)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "urine test is positive or cannot be confirmed as negative",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "positive",
                                "cannot be confirmed as negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "a serum pregnancy test will be required",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "requirement for test",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Willing to receive a tetanus vaccination if subject has not had one =< 1 year prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Willing to receive a tetanus vaccination",
                    "criterion": "willingness to receive tetanus vaccination",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if subject has not had one =< 1 year prior to pre-registration",
                    "criterion": "tetanus vaccination history",
                    "requirements": [
                        {
                            "requirement_type": "time since last tetanus vaccination",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        },
                        {
                            "requirement_type": "relative to",
                            "expected_value": "prior to pre-registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Willing to provide mandatory tissue specimens per protocol",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide mandatory tissue specimens per protocol",
                    "criterion": "willingness to provide tissue specimens",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "specimen type",
                            "expected_value": "tissue"
                        },
                        {
                            "requirement_type": "protocol compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy (obtained =< 28 days prior to pre-registration)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy (obtained =< 28 days prior to pre-registration)",
                    "criterion": "INR or PT and aPTT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of test",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy (obtained =< 28 days prior to pre-registration)",
                    "criterion": "PT or PTT (for patients on anticoagulant therapy)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within target range of therapy"
                        },
                        {
                            "requirement_type": "time of test",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "format",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION COHORT 1 ONLY: Has cancer progression after at least one line of standard of care systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Has cancer progression",
                    "criterion": "cancer progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least one line of standard of care systemic treatment",
                    "criterion": "prior standard of care systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of lines completed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Negative pregnancy test done =< 7 days prior to pre-registration for persons of childbearing potential only",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test done =< 7 days prior to pre-registration",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for persons of childbearing potential only",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Willing to provide mandatory tissue specimens for correlative research",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide mandatory tissue specimens for correlative research",
                    "criterion": "tissue specimen provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requirement",
                            "expected_value": "mandatory"
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "correlative research"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Calculated creatinine clearance >= 50 ml/min using the Cockcroft-Gault formula (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance >= 50 ml/min using the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "creatinine clearance measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease or non-measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Tumor lesions in a previously irradiated area are not considered measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "measurable disease status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor lesions in a previously irradiated area are not considered ... non-measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "non-measurable disease status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION COHORT 1 ONLY: Has cancer progression after at least one line of standard of care systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "PRE-REGISTRATION COHORT 1 ONLY: Has cancer progression after at least one line of standard of care systemic treatment",
                    "criterion": "cancer progression after standard of care systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior lines of standard of care systemic treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: This includes mandatory fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing unless patient had sequencing under Mayo Institutional Review Board (IRB) protocol #13-000942, #14-004094, or #21-007742 and has been identified for potential production of REAL Neo vaccine. Patients who had sequencing under Mayo IRB protocol #13-000942, #14-004094, or #21-007742 and have been identified for potential production of REAL Neo vaccine are allowed to proceed with neoantigen production.",
            "criterions": [
                {
                    "exact_snippets": "mandatory fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing",
                    "criterion": "fresh tissue specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at pre-registration"
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": [
                                "complete exome sequencing",
                                "transcriptome sequencing"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient had sequencing under Mayo Institutional Review Board (IRB) protocol #13-000942, #14-004094, or #21-007742 and has been identified for potential production of REAL Neo vaccine",
                    "criterion": "prior sequencing under specific Mayo IRB protocols and identification for REAL Neo vaccine production",
                    "requirements": [
                        {
                            "requirement_type": "prior sequencing protocol",
                            "expected_value": [
                                "#13-000942",
                                "#14-004094",
                                "#21-007742"
                            ]
                        },
                        {
                            "requirement_type": "identification for REAL Neo vaccine production",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Creatinine =< 1.5 x ULN OR calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to pre-registration)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to pre-registration)",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        },
                        {
                            "requirement_type": "time of assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 X 10^9/L (obtained =< 28 days prior to pre-registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 X 10^9/L (obtained =< 28 days prior to pre-registration)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1500,
                                        "unit": "mm^3"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1.5,
                                        "unit": "10^9/L"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 28 days prior to pre-registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION COHORT 2 ONLY: Pembrolizumab without chemotherapy remains as a reasonable treatment option at the treating physician's decision",
            "criterions": [
                {
                    "exact_snippets": "Pembrolizumab without chemotherapy remains as a reasonable treatment option at the treating physician's decision",
                    "criterion": "pembrolizumab without chemotherapy as treatment option",
                    "requirements": [
                        {
                            "requirement_type": "treating physician decision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: ECOG Performance Status (PS) 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status (PS) 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Measurable disease as defined by RECIST (version 1.1) criteria",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by RECIST (version 1.1) criteria",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "RECIST (version 1.1) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Anticipated life expectancy of > 6 months",
            "criterions": [
                {
                    "exact_snippets": "Anticipated life expectancy of > 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "anticipated duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle",
            "criterions": [
                {
                    "exact_snippets": "Willing to employ a highly effective method of contraception from the time of pre-registration through 6 months after the final vaccine cycle",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of pre-registration through 6 months after the final vaccine cycle"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Willing to receive a tetanus vaccination if subject has not had one =< 1 year prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Willing to receive a tetanus vaccination",
                    "criterion": "willingness to receive tetanus vaccination",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if subject has not had one =< 1 year prior to pre-registration",
                    "criterion": "tetanus vaccination history",
                    "requirements": [
                        {
                            "requirement_type": "time since last tetanus vaccination",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF",
                    "criterion": "actionable genomic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "EGFR",
                                "ALK",
                                "MET",
                                "ROS-1",
                                "RET",
                                "NTRK",
                                "KRAS",
                                "BRAF"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have also received and progressed on at least one line of prior FDA-approved targeted therapy",
                    "criterion": "prior FDA-approved targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "progressed_on",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy",
                    "criterion": "PT/INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless patient is receiving anticoagulant therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless patient is receiving anticoagulant therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy",
                    "criterion": "INR or aPTT (for patients on anticoagulant therapy)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within target range of therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 14 days prior to registration",
                    "criterion": "timing of laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION COHORT 2 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies that pembrolizumab is FDA approved indication (including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC) or other solid tumors that will benefit from pembrolizumab per the treating physician's judgement.",
            "criterions": [
                {
                    "exact_snippets": "REGISTRATION COHORT 2 ONLY",
                    "criterion": "registration cohort",
                    "requirements": [
                        {
                            "requirement_type": "cohort number",
                            "expected_value": "2"
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologically confirmed",
                    "criterion": "histological confirmation of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable locally advanced or metastatic solid malignancies",
                    "criterion": "solid malignancy",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "pembrolizumab is FDA approved indication (including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC)",
                    "criterion": "malignancy type",
                    "requirements": [
                        {
                            "requirement_type": "FDA approved pembrolizumab indication",
                            "expected_value": [
                                "melanoma",
                                "non-small cell lung cancer",
                                "head and neck squamous cell cancer",
                                "urothelial carcinoma",
                                "microsatellite instability-high tumor",
                                "gastric or gastroesophageal junction adenocarcinoma",
                                "cervical cancer",
                                "hepatocellular carcinoma",
                                "merkel cell carcinoma",
                                "renal cell carcinoma",
                                "endometrial carcinoma",
                                "tumor mutational burden-high cancer",
                                "cutaneous squamous cell carcinoma",
                                "triple-negative breast cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other solid tumors that will benefit from pembrolizumab per the treating physician's judgement",
                    "criterion": "other solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "expected benefit from pembrolizumab",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treating physician's judgement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION COHORT 1 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies",
            "criterions": [
                {
                    "exact_snippets": "PRE-REGISTRATION COHORT 1 ONLY: Histologically confirmed",
                    "criterion": "histological confirmation of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable locally advanced or metastatic solid malignancies",
                    "criterion": "solid malignancy",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Anticipated life expectancy of > 6 months",
            "criterions": [
                {
                    "exact_snippets": "Anticipated life expectancy of > 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: It should not be tumor which was radiated in the past.",
            "criterions": [
                {
                    "exact_snippets": "should not be tumor which was radiated in the past",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "prior radiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION COHORT 2 ONLY: Patient is eligible to receive pembrolizumab with or without chemotherapy per the treating physician's judgement or has been on pembrolizumab through compassionate use",
            "criterions": [
                {
                    "exact_snippets": "Patient is eligible to receive pembrolizumab with or without chemotherapy per the treating physician's judgement",
                    "criterion": "eligibility to receive pembrolizumab with or without chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by",
                            "expected_value": "treating physician's judgement"
                        }
                    ]
                },
                {
                    "exact_snippets": "has been on pembrolizumab through compassionate use",
                    "criterion": "prior pembrolizumab use through compassionate use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease or non-measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Tumor lesions in a previously irradiated area are not considered measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor lesions in a previously irradiated area are not considered ... non-measurable disease",
                    "criterion": "tumor lesions in previously irradiated area",
                    "requirements": [
                        {
                            "requirement_type": "non-measurability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF",
                    "criterion": "actionable genomic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "EGFR",
                                "ALK",
                                "MET",
                                "ROS-1",
                                "RET",
                                "NTRK",
                                "KRAS",
                                "BRAF"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have also received and progressed on at least one line of prior FDA-approved targeted therapy",
                    "criterion": "prior FDA-approved targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see below limits for inclusion) or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1, except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo)",
            "criterions": [
                {
                    "exact_snippets": "Recovered from all toxicities associated with prior treatment to acceptable baseline status",
                    "criterion": "toxicities associated with prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": "acceptable baseline status"
                        }
                    ]
                },
                {
                    "exact_snippets": "for laboratory toxicity see below limits for inclusion",
                    "criterion": "laboratory toxicity",
                    "requirements": [
                        {
                            "requirement_type": "meets_inclusion_limits",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade of 0 or 1",
                    "criterion": "NCI CTCAE v5.0 toxicity grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "grade"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for toxicities not considered a safety risk per treating investigator (e.g., alopecia or vitiligo)",
                    "criterion": "toxicities not considered a safety risk per treating investigator",
                    "requirements": [
                        {
                            "requirement_type": "exemption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Soft tissue lesion amenable for adequate tissue sampling",
            "criterions": [
                {
                    "exact_snippets": "Soft tissue lesion amenable for adequate tissue sampling",
                    "criterion": "soft tissue lesion",
                    "requirements": [
                        {
                            "requirement_type": "amenability for adequate tissue sampling",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Willing to provide mandatory blood specimens for correlative research",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide mandatory blood specimens for correlative research",
                    "criterion": "blood specimen provision for correlative research",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "specimen type",
                            "expected_value": "blood"
                        },
                        {
                            "requirement_type": "requirement status",
                            "expected_value": "mandatory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION COHORT 1 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histology"
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable",
                    "criterion": "tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "solid malignancies",
                    "criterion": "malignancy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "solid"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION COHORT 2 ONLY: Histologically confirmed unresectable locally advanced or metastatic solid malignancies that pembrolizumab is Food and Drug Administration (FDA) approved indication including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC) or other solid tumors that will benefit from pembrolizumab per the treating physician's judgment.",
            "criterions": [
                {
                    "exact_snippets": "PRE-REGISTRATION COHORT 2 ONLY",
                    "criterion": "cohort",
                    "requirements": [
                        {
                            "requirement_type": "membership",
                            "expected_value": "pre-registration cohort 2 only"
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologically confirmed",
                    "criterion": "histological confirmation of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable locally advanced or metastatic solid malignancies",
                    "criterion": "solid malignancy",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "pembrolizumab is Food and Drug Administration (FDA) approved indication including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HSNCC), urothelial carcinoma, any microsatellite instability (MSI)-high tumor, gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), merkel cell carcinoma (MCC), renal cell carcinoma (RCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma (cSCC), and triple-negative breast cancer (TNBC)",
                    "criterion": "malignancy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "melanoma",
                                "non-small cell lung cancer (NSCLC)",
                                "head and neck squamous cell cancer (HSNCC)",
                                "urothelial carcinoma",
                                "microsatellite instability (MSI)-high tumor",
                                "gastric or gastroesophageal junction (GEJ) adenocarcinoma",
                                "cervical cancer",
                                "hepatocellular carcinoma (HCC)",
                                "merkel cell carcinoma (MCC)",
                                "renal cell carcinoma (RCC)",
                                "endometrial carcinoma",
                                "tumor mutational burden-high (TMB-H) cancer",
                                "cutaneous squamous cell carcinoma (cSCC)",
                                "triple-negative breast cancer (TNBC)"
                            ]
                        },
                        {
                            "requirement_type": "pembrolizumab FDA approval",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other solid tumors that will benefit from pembrolizumab per the treating physician's judgment",
                    "criterion": "other solid tumor with potential benefit from pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "benefit from pembrolizumab",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treating physician's judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Pregnant person",
            "criterions": [
                {
                    "exact_snippets": "Pregnant person",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing or active infection",
            "criterions": [
                {
                    "exact_snippets": "Ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing persons",
            "criterions": [
                {
                    "exact_snippets": "Nursing persons",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation =< 2 weeks prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Radiation =< 2 weeks prior to registration",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix",
            "criterions": [
                {
                    "exact_snippets": "Non-melanotic skin cancer",
                    "criterion": "skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "melanotic status",
                            "expected_value": "non-melanotic"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinoma-in-situ of the cervix",
                    "criterion": "carcinoma-in-situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major Surgery =< 4 weeks prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Major Surgery =< 4 weeks prior to registration",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",
            "criterions": [
                {
                    "exact_snippets": "investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
                    "criterion": "investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "genotoxicity effects on fetus/newborn",
                            "expected_value": "unknown"
                        },
                        {
                            "requirement_type": "mutagenicity effects on fetus/newborn",
                            "expected_value": "unknown"
                        },
                        {
                            "requirement_type": "teratogenicity effects on fetus/newborn",
                            "expected_value": "unknown"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Person of childbearing potential who are unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle",
            "criterions": [
                {
                    "exact_snippets": "Person of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from registration through 6 months after the final vaccine cycle"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator judgment of appropriateness for study entry or interference with assessment of safety and toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Central nervous system metastases that are untreated, symptomatic, or require steroids > 10 mg daily prednisone equivalent",
            "criterions": [
                {
                    "exact_snippets": "Central nervous system metastases that are untreated",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that are ... symptomatic",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that ... require steroids > 10 mg daily prednisone equivalent",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "steroid requirement",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Patients with history of stable treated brain metastases are eligible. Stable treated metastases are defined as follows: No evidence of progression for >= 4 weeks on brain imaging (either magnetic resonance imaging [MRI] or computed tomography [CT] scan)",
            "criterions": [
                {
                    "exact_snippets": "history of stable treated brain metastases are eligible",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history of stable treated metastases",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "No evidence of progression for >= 4 weeks on brain imaging (either magnetic resonance imaging [MRI] or computed tomography [CT] scan)",
                    "criterion": "brain metastases progression",
                    "requirements": [
                        {
                            "requirement_type": "progression-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "magnetic resonance imaging (MRI)",
                                "computed tomography (CT) scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Other active malignancy =< 3 years prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy =< 3 years prior to pre-registration",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or activity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",
            "criterions": [
                {
                    "exact_snippets": "this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
                    "criterion": "investigational agent with unknown genotoxic, mutagenic, and teratogenic effects",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: History of myocardial infarction =< 6 months prior to pre-registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction =< 6 months prior to pre-registration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "requires_ongoing_maintenance_therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication_for_therapy",
                            "expected_value": "life-threatening ventricular arrhythmias"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with celiac disease controlled with diet modification are not excluded",
            "criterions": [
                {
                    "exact_snippets": "vitiligo ... not requiring systemic treatment within the past 30 days are not excluded",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systemic treatment time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Graves disease ... not requiring systemic treatment within the past 30 days are not excluded",
                    "criterion": "Graves disease",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systemic treatment time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "psoriasis not requiring systemic treatment within the past 30 days are not excluded",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systemic treatment time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "celiac disease controlled with diet modification are not excluded",
                    "criterion": "celiac disease",
                    "requirements": [
                        {
                            "requirement_type": "disease control method",
                            "expected_value": "diet modification"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure with New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure with New York Heart Association class III or IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate to severe objective evidence of cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "objective evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Active autoimmune diseases that require chronic systemic steroids (> 10 mg daily prednisone equivalent) or immunosuppressive agents",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune diseases",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "require chronic systemic steroids (> 10 mg daily prednisone equivalent)",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "require ... immunosuppressive agents",
                    "criterion": "immunosuppressive agent use",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Evidence of leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Evidence of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy), or a history of rhabdomyolysis",
            "criterions": [
                {
                    "exact_snippets": "Neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy)",
                    "criterion": "neuromuscular disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of rhabdomyolysis",
                    "criterion": "history of rhabdomyolysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy",
            "criterions": [
                {
                    "exact_snippets": "Immunocompromised patients",
                    "criterion": "immunocompromised status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients known to be human immunodeficiency virus (HIV) positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving antiretroviral therapy",
                    "criterion": "antiretroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other conditions that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Any other conditions that would limit compliance with study requirements",
                    "criterion": "other conditions limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant persons",
            "criterions": [
                {
                    "exact_snippets": "Pregnant persons",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Persons of childbearing potential who are unwilling to employ adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Persons of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to employ adequate contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator judgment of appropriateness for study entry or interference with assessment of safety and toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease",
            "criterions": [
                {
                    "exact_snippets": "Inhaled or topical steroids ... are permitted",
                    "criterion": "inhaled or topical steroid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adrenal replacement steroid doses > 10 mg daily prednisone equivalent ... are permitted",
                    "criterion": "adrenal replacement steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of active autoimmune disease",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Requirement for systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications =< 14 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Requirement for systemic corticosteroids (> 10 mg daily prednisone equivalent) ... =< 14 days prior to registration",
                    "criterion": "systemic corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Requirement for ... other immunosuppressive medications =< 14 days prior to registration",
                    "criterion": "immunosuppressive medication requirement",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live vaccine =< 30 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Received a live vaccine =< 30 days prior to registration",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative to registration",
                            "expected_value": "prior"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing person unwilling to stop breast feeding",
            "criterions": [
                {
                    "exact_snippets": "Nursing person unwilling to stop breast feeding",
                    "criterion": "breast feeding",
                    "requirements": [
                        {
                            "requirement_type": "willingness to stop",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Any prior hypersensitivity or adverse reaction to GM-CSF",
            "criterions": [
                {
                    "exact_snippets": "Any prior hypersensitivity or adverse reaction to GM-CSF",
                    "criterion": "hypersensitivity to GM-CSF",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior hypersensitivity or adverse reaction to GM-CSF",
                    "criterion": "adverse reaction to GM-CSF",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Acute, reversible effect(s) of prior therapy not recovered to baseline regardless of interval since last treatment",
            "criterions": [
                {
                    "exact_snippets": "Acute, reversible effect(s) of prior therapy not recovered to baseline regardless of interval since last treatment",
                    "criterion": "acute, reversible effects of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "not recovered to baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant cardiac arrhythmia or unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Significant cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stroke =< 3 months prior to pre-registration",
            "criterions": [
                {
                    "exact_snippets": "Stroke =< 3 months prior to pre-registration",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to pre-registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: CTCAE >= Grade 3 treatment-emergent adverse event (TEAE) to prior checkpoint inhibitor, TEAE requiring systemic corticosteroids (> 10 mg daily prednisone equivalent), or permanent treatment discontinuation due to toxicity",
            "criterions": [
                {
                    "exact_snippets": "CTCAE >= Grade 3 treatment-emergent adverse event (TEAE) to prior checkpoint inhibitor",
                    "criterion": "treatment-emergent adverse event (TEAE) to prior checkpoint inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "TEAE requiring systemic corticosteroids (> 10 mg daily prednisone equivalent)",
                    "criterion": "treatment-emergent adverse event (TEAE) requiring systemic corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "systemic corticosteroid dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "permanent treatment discontinuation due to toxicity",
                    "criterion": "permanent treatment discontinuation due to toxicity",
                    "requirements": [
                        {
                            "requirement_type": "permanent discontinuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm, except for pembrolizumab",
            "criterions": [
                {
                    "exact_snippets": "Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm, except for pembrolizumab",
                    "criterion": "receipt of investigational agent for primary neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "pembrolizumab"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Uncontrolled illness including, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled illness",
                    "criterion": "illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PRE-REGISTRATION: Known history of active autoimmune disease that has required systemic treatment in the =<30 days (i.e., with use of disease modifying agents, corticosteroids >10 mg daily prednisone equivalent, or other immunosuppressive drugs) prior to pre-registration.",
            "criterions": [
                {
                    "exact_snippets": "Known history of active autoimmune disease",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in the =<30 days (i.e., with use of disease modifying agents, corticosteroids >10 mg daily prednisone equivalent, or other immunosuppressive drugs) prior to pre-registration",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "disease modifying agents",
                                "corticosteroids >10 mg daily prednisone equivalent",
                                "other immunosuppressive drugs"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Palliative radiation therapy for symptoms control including, but not limited to, bone metastatic lesion radiation therapy is allowed, but the last dose of radiation therapy should be more than 14 days from the first dose of vaccination on the study",
            "criterions": [
                {
                    "exact_snippets": "Palliative radiation therapy for symptoms control ... is allowed",
                    "criterion": "palliative radiation therapy for symptom control",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bone metastatic lesion radiation therapy is allowed",
                    "criterion": "bone metastatic lesion radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the last dose of radiation therapy should be more than 14 days from the first dose of vaccination on the study",
                    "criterion": "interval between last dose of radiation therapy and first dose of vaccination",
                    "requirements": [
                        {
                            "requirement_type": "minimum interval",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, experimental drugs (except for pembrolizumab), or small molecules inhibitors (except for endocrine therapies) =< 3 weeks prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... =< 3 weeks prior to registration",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "experimental drugs (except for pembrolizumab) ... =< 3 weeks prior to registration",
                    "criterion": "experimental drugs (except for pembrolizumab)",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "small molecules inhibitors (except for endocrine therapies) =< 3 weeks prior to registration",
                    "criterion": "small molecule inhibitors (except for endocrine therapies)",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Any of the following prior therapies:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following prior therapies",
                    "criterion": "prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychiatric illness/social situations",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social situations",
                    "criterion": "social situations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Recent anti-PD1 or anti-PD-L1, such as pembrolizumab, nivolumab, atezolizumab, and durvalumab, is allowed, but the last dose of anti-PD-1 or anti-PD-L1 treatment should be more than 21 days from first dose of vaccination on the study (for Cohort 2 only)",
            "criterions": [
                {
                    "exact_snippets": "Recent anti-PD1 or anti-PD-L1, such as pembrolizumab, nivolumab, atezolizumab, and durvalumab, is allowed",
                    "criterion": "prior anti-PD-1 or anti-PD-L1 treatment",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the last dose of anti-PD-1 or anti-PD-L1 treatment should be more than 21 days from first dose of vaccination on the study (for Cohort 2 only)",
                    "criterion": "interval between last anti-PD-1 or anti-PD-L1 dose and first vaccination dose",
                    "requirements": [
                        {
                            "requirement_type": "interval",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer",
            "criterions": [
                {
                    "exact_snippets": "history of prior malignancy",
                    "criterion": "history of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be receiving other specific treatment for their cancer",
                    "criterion": "receiving other specific treatment for cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* PRE-REGISTRATION: Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases (obtained =< 28 days prior to pre-registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate transaminase (AST) ... =< 3 x ULN or =< 5 x ULN for patients with liver metastases (obtained =< 28 days prior to pre-registration)",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) ... =< 3 x ULN or =< 5 x ULN for patients with liver metastases (obtained =< 28 days prior to pre-registration)",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to pre-registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "= < 5 x ULN for patients with liver metastases",
                    "criterion": "aspartate transaminase (AST) level in patients with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "= < 5 x ULN for patients with liver metastases",
                    "criterion": "alanine transaminase (ALT) level in patients with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 14 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 14 days prior to registration)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate transaminase (AST) ... =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 14 days prior to registration)",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "=<= 5 x ULN for patients with liver involvement",
                    "criterion": "ALT or AST level in patients with liver involvement",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": "obtained =< 14 days prior to registration"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}